SuperNuclease®: Efficient Residual DNA and RNA Removal for Biologics Manufacturing
Residual host-cell DNA and RNA can complicate nearly every stage of biologics development, from cell lysis and clarification to viral-vector purification and final-product quality control.
Long nucleic acid molecules increase sample viscosity, trap cellular debris, promote aggregation, and interfere with downstream purification. They must also be controlled as process-related impurities in many biologics manufacturing workflows.
SuperNuclease® is a genetically engineered, nonspecific endonuclease developed to efficiently digest DNA and RNA in research and bioprocessing samples. By breaking nucleic acids into short oligonucleotides, SuperNuclease can reduce lysate viscosity, facilitate clarification, and support residual host-cell nucleic acid control.
Why residual nucleic acid removal matters
Biological products are commonly produced using bacterial, yeast, insect, or mammalian host cells. When these cells are disrupted (or when they release material during culture) host-cell DNA and RNA enter the process stream.
These nucleic acids can create several challenges:
- Increased viscosity in cell lysates
- Difficult mixing, pumping, and sample transfer
- Slower centrifugation or filtration
- Entrapment of proteins, viral particles, and cell debris
- Reduced chromatography performance
- Cell or particle aggregation
- Greater residual host-cell DNA burden downstream
Residual host-cell DNA is also a recognized process-related impurity. Regulators expect manufacturers to characterize their production substrates, establish appropriate impurity specifications, and demonstrate that the manufacturing process consistently reduces residual DNA to acceptable levels.
Importantly, acceptable limits are product-specific. They can depend on the host-cell substrate, manufacturing process, route of administration, intended use, DNA fragment size, analytical method, and applicable regulatory framework. The World Health Organization recommends establishing product-specific limits in consultation with the relevant regulatory authority.
A nuclease step can form part of this broader impurity-control strategy by reducing both the quantity and size of residual nucleic acid fragments.
What is SuperNuclease?
SuperNuclease is an engineered endonuclease derived from the extracellular nuclease of Serratia marcescens. It nonspecifically hydrolyzes nucleic acids rather than recognizing a particular sequence.
The enzyme can digest multiple nucleic acid forms, including:
- Single-stranded DNA
- Double-stranded DNA
- Linear DNA
- Circular and supercoiled DNA
- Single-stranded RNA
- Double-stranded RNA
SuperNuclease cleaves internal phosphodiester bonds and reduces nucleic acids to short oligonucleotides, typically approximately three to five bases in length with 5′-monophosphate termini.
This broad substrate compatibility allows one enzyme to address diverse nucleic acid impurities without requiring separate DNase and RNase treatments.
How SuperNuclease improves cell lysate processing
Cell disruption releases large quantities of genomic DNA. These long DNA molecules become entangled and bind water, producing thick, stringy lysates that are difficult to pipette, mix, centrifuge, or filter.
SuperNuclease fragments the released DNA and RNA into much smaller pieces. As the nucleic acid network is broken down, the viscosity of the lysate decreases.
This can provide several practical benefits:
Easier sample handling
Lower-viscosity lysates are easier to pipette, mix, transfer, and scale. This is particularly useful when processing dense microbial cultures or high-cell-density mammalian samples.
More efficient clarification
Reducing nucleic acid-driven viscosity can help separate soluble material from cell debris during centrifugation or filtration.
Improved access to target molecules
DNA and RNA can entangle proteins, inclusion bodies, viral particles, and other macromolecular complexes. Nuclease treatment can help release these materials into a more manageable process stream.
Reduced aggregation
Extracellular nucleic acids may contribute to cell and particle aggregation. Digesting them can help reduce unwanted clumping in compatible workflows.
More consistent downstream processing
A less viscous and more homogeneous sample may improve reproducibility during filtration, chromatography, analytical testing, and protein purification.
Applications in biologics and life science research
SuperNuclease can be incorporated into a range of research and manufacturing workflows.
Recombinant protein purification
During bacterial, yeast, insect, or mammalian cell lysis, SuperNuclease can help reduce viscosity before clarification and chromatography. This may simplify the recovery of recombinant proteins and improve sample handling.
Viral-vector manufacturing
Host-cell DNA can remain associated with viral particles or become trapped within the harvest matrix. Nuclease treatment is frequently evaluated during the production of adeno-associated virus, lentivirus, adenovirus, and other viral vectors.
By degrading accessible host-cell nucleic acids, SuperNuclease can support clarification and downstream purification. The treatment step must still be optimized to protect vector integrity and meet the requirements of the specific process.
Vaccine production
Vaccines produced in cell-based systems may contain residual DNA originating from the production substrate. SuperNuclease can be evaluated as part of a validated process for reducing host-cell nucleic acid impurities.
Cell and gene therapy
Cell and gene therapy manufacturing often involves concentrated cell cultures, viral vectors, and complex process matrices. These workflows can benefit from efficient nucleic acid digestion, particularly when viscosity and residual host-cell DNA affect processing.
Cell lysate preparation
SuperNuclease can also be used in research-scale protein extraction, Western blot sample preparation, and other applications where genomic DNA makes lysates difficult to handle.
SuperNuclease product formats
Sino Biological provides several SuperNuclease formats for different research and manufacturing requirements.
| Product | Catalog number | Format | Intended use |
| SuperNuclease | SSNP01 | RUO-grade lyophilized powder | Research and process development |
| GMP-grade SuperNuclease | GMP-SSNP01 | Liquid formulation | Biologics process development and manufacturing |
| GMP-grade SuperNuclease with glycerol | GMP-SSNP01-G | Liquid with 50% glycerol | Workflows requiring extended frozen-solution stability |
| Animal-free GMP-grade SuperNuclease | GMP-SSNP01-AF | Animal-origin-free liquid formulation | Processes with animal-origin risk-control requirements |
The GMP-grade products are manufactured under quality systems designed to support regulated bioprocessing. Sino Biological reports that a Drug Master File for SuperNuclease has been filed with the US FDA under DMF number 035978.
A DMF filing can help customers reference supporting manufacturing and quality information during regulatory submissions. It should not be interpreted as FDA approval of the reagent or of a customer’s manufacturing process.
Recommended operating conditions
SuperNuclease activity depends on factors such as magnesium concentration, pH, temperature, salt, detergent, and sample composition.
The following ranges provide a starting point for process development:
| Condition | Optimal range* | Broader effective range** |
| Magnesium ions | 1–2 mM | 1–10 mM |
| pH | 8.0–9.5 | 5.5–9.5 |
| Temperature | 37°C | 0–50°C |
| Monovalent cations | 0–100 mM | 0–400 mM |
| Phosphate | 0 mM | 0–50 mM |
| Tween 20 | 0–0.8% | Approximately 0.8% |
*Optimal conditions are those under which the enzyme reportedly retains at least 90% activity.
**Effective conditions are those under which the enzyme retains measurable activity above the stated internal threshold.
These ranges should be treated as general guidance. Enzyme concentration, incubation time, mixing, nucleic acid burden, and buffer composition should be optimized in the actual process matrix.
When to consider a salt-active nuclease
Standard nucleases may lose activity as ionic strength increases. This can be a concern in workflows that use elevated salt concentrations to disrupt chromatin, release viral particles, prevent aggregation, or support purification.
Sino Biological’s Salt Active SuperNuclease is designed for nucleic acid degradation in higher-salinity environments. It maintains activity across approximately 200–600 mM salt, making it an option for workflows in which conventional nuclease activity is reduced by ionic strength.
SuperNuclease® Pro offers another option for demanding bioprocessing and molecular-diagnostic applications. It is engineered for enhanced catalytic performance and retains activity in challenging high-salt conditions, including approximately 300–500 mM NaCl.
Selection should be based on the actual process conditions rather than product name alone. A side-by-side study in the intended matrix can help determine the most suitable nuclease, dose, and incubation time.
Detecting residual nuclease after treatment
Nuclease treatment removes unwanted DNA and RNA, but the enzyme itself may subsequently need to be monitored as a process-related impurity.
The SuperNuclease ELISA Kit, catalog number KIT-SSNP01, is designed to quantify residual nuclease in process intermediates, semi-finished material, and final biological products.
Reported kit characteristics include:
- Quantitative detection range of 46.87–3,000 pg/mL
- Detection limit of 14.55 pg/mL
- Recovery range of 80–120%
- Monoclonal-antibody-based capture and detection
- Compatibility with SuperNuclease and selected nuclease products from other suppliers
A residual-nuclease assay can support process characterization by helping demonstrate enzyme clearance during downstream purification.
Building a robust nuclease-treatment step
A well-designed nuclease step should be optimized as part of the complete manufacturing process.
Key parameters include:
- Treatment location: Determine whether the enzyme should be added during lysis, after harvest, before clarification, or at another process stage.
- Enzyme concentration: Establish a dose that achieves the required nucleic acid reduction without unnecessary reagent use.
- Incubation time and temperature: Balance digestion efficiency against process time and product stability.
- Magnesium availability: Confirm that sufficient free magnesium is available, especially in buffers containing chelators.
- Salt and detergent compatibility: Test the complete process buffer rather than evaluating individual ingredients in isolation.
- Mixing: Ensure the enzyme contacts the full sample volume, particularly in viscous or high-density materials.
- Product quality: Confirm that treatment does not adversely affect the activity, structure, recovery, or potency of the target product.
- Residual impurity testing: Measure both remaining host-cell nucleic acid and residual nuclease where appropriate.
- Clearance validation: Demonstrate that downstream purification consistently removes the nuclease and digested nucleic acid fragments to the required levels.
Supporting regulatory-aligned process development
No reagent can make a manufacturing process compliant by itself. Regulatory acceptability depends on the complete process, its control strategy, validated analytical methods, manufacturing consistency, and the requirements of the intended product.
However, selecting a well-characterized nuclease with appropriate quality documentation can simplify process development and regulatory preparation.
Depending on the product and development stage, useful supplier documentation may include:
- Identity and purity data
- Specific-activity testing
- Endotoxin specifications
- Sterility and mycoplasma testing
- Residual host-cell protein testing
- Animal-origin statements
- Stability information
- Lot-specific certificates of analysis
- GMP or quality-system documentation
- Drug Master File support
Manufacturers should define acceptance criteria in consultation with their quality and regulatory teams.
Frequently asked questions
Does SuperNuclease digest both DNA and RNA?
Yes. SuperNuclease is a nonspecific endonuclease that digests single- and double-stranded DNA and RNA, including linear, circular, and supercoiled forms.
Can SuperNuclease reduce cell lysate viscosity?
Yes. By fragmenting the long DNA and RNA molecules released during cell disruption, SuperNuclease can substantially reduce nucleic acid-driven lysate viscosity.
Does SuperNuclease require magnesium?
SuperNuclease is magnesium-dependent. A magnesium concentration of approximately 1–2 mM is reported as optimal, although the effective range may extend from 1–10 mM depending on the process matrix.
Can SuperNuclease be used in high-salt buffers?
Standard SuperNuclease retains activity across a range of salt concentrations, but performance decreases as ionic strength rises. For processes operating at higher salt concentrations, Salt Active SuperNuclease or SuperNuclease Pro may be more appropriate.
Is SuperNuclease suitable for GMP manufacturing?
Sino Biological offers GMP-grade SuperNuclease formats for bioprocessing applications. Suitability must still be assessed for the intended process, product, development stage, and regulatory jurisdiction.
How can residual SuperNuclease be measured?
Residual enzyme can be quantified using the SuperNuclease ELISA Kit. The assay may be used to support process characterization and demonstrate nuclease clearance.
Simplify nucleic acid removal with SuperNuclease
Efficient nucleic acid digestion can improve more than residual DNA levels. It can also reduce viscosity, facilitate clarification, minimize aggregation, and make downstream processing more predictable.
With RUO-grade, GMP-grade, animal-free, glycerol-containing, and salt-active formats available, the SuperNuclease portfolio supports workflows ranging from laboratory-scale protein extraction to advanced biologics manufacturing.
Explore SuperNuclease solutions from Sino Biological or contact our team to discuss your cell lysate, viral-vector, vaccine, or biologics purification workflow.
References
- World Health Organization. Recommendations for the Evaluation of Animal Cell Cultures as Substrates for the Manufacture of Biological Medicinal Products and for the Characterization of Cell Banks. WHO Technical Report Series No. 978, Annex 3.
- US Food and Drug Administration. Direct Analysis of Residual Host Cell DNA by Droplet Digital PCR in Biologic Drugs Produced in E. coli.
- Sino Biological. SuperNuclease product and technical information.
- Sino Biological. SuperNuclease Pro launch information.
